La cadena de opciones muestra datos clave de las opciones de acciones de Genelux a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Genelux..

Genelux (NASDAQ:GNLX) Bolsa, Cadena de Opciones

Genelux

Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.

Genelux Corp

SJW Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NASDAQ">SJW</a>) affirms FY2025 Adj EPS guidance from $2.90-$3.00 to $2.90-$3.00 vs $2.97 analyst estimate..

News

Guidance

SJW Gr Affirms FY2025 Adj EPS Guidance of $2.90-$3.00 vs $2.97 Est

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) is looking for Q2 Adj EPS of $0.41-$0.64 vs $0.52 analyst estimate. sees sales of $610.000 million-$680.000 million vs $643.53 million analyst estimate.

Teradyne Sees Q2 Adj EPS $0.41-$0.64 vs $0.52 Est; Sees Sales $610.000M-$680.000M vs $643.53M Est

SJW Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJW#NYSE">SJW</a>) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $0.36 by 38.89 percent. This is a 38.89 percent increase over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $167.60 million which beat the analyst consensus estimate of $159.03 million by 5.39 percent. This is a 12.19 percent increase over sales of $149.38 million the same period last year.

Earnings

Earnings Beats

SJW Gr Q1 Adj. EPS $0.50 Beats $0.36 Estimate, Sales $167.60M Beat $159.03M Estimate

Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.62 by 20.97 percent. This is a 47.06 percent increase over earnings of $0.51 per share from the same period last year. The company reported quarterly sales of $685.68 million which beat the analyst consensus estimate of $680.51 million by 0.76 percent. This is a 14.31 percent increase over sales of $599.82 million the same period last year.

Teradyne Q1 Adj. EPS $0.75 Beats $0.62 Estimate, Sales $685.68M Beat $680.51M Estimate

Transocean, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RIG#NYSE">RIG</a>) released its first-quarter results after Monday's closing bell. Here's a look at the details<a href="https://www.benzinga.com/pressreleases/25/04/g45052677/transocean-ltd-reports-first-quarter-2025-results"> from the report. </a>
The Details: Transocean reported first-quarter losses of 10 cents per share, which missed the analyst consensus estimate for losses of nine cents. Quarterly revenue clocked in at $906 million, beating the consensus estimate of $885.7 million.
Read Next: <a href="https://www.benzinga.com/news/global/25/04/44952117/apple-and-meta-fined-nearly-800-million-for-violating-european-unions-digital-markets-act?utm_source=articleShare">Apple And Meta Fined Nearly $800 Million For Violating European Union&#8217;s Digital Markets Act</a>&nbsp;
For the first quarter, Transocean reported: 
<ul>
<li>Contract drilling revenues for the quarter decreased sequentially by $46 million to $906 million. </li>
<li>Operating and maintenance expense was $618 million, compared with $579 million in the prior quarter. The sequential increase was the result of an unfavorable legal outcome in the first quarter, a favorable legal settlement in the fourth quarter and increased costs related to a rig in shipyard, partially offset by lower in-service maintenance costs across the fleet.</li>
<li>General and administrative expense was $50 million, down from $56 million in the fourth quarter, due primarily to decreased legal and professional fees.</li>
</ul>
&#8220;The Transocean team delivered a solid quarter, with an adjusted EBITDA of $244 million on revenues of $906 million,&#8221; said CEO Jeremy Thigpen. &#8220;We also improved our balance sheet with the repayment of $210 million in outstanding debt.&#8221;
&#8220;While uncertain macroeconomic conditions have resulted in near-term market volatility, including commodity prices, Transocean is very well-positioned to navigate this evolving landscape.&nbsp;In addition to continuing to deliver strong operating performance across our highly contracted fleet, we remain engaged in constructive conversations with our customers on opportunities several years in the future,&#8221; Thigpen added. 
RIG Price Action: According to data from <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Transocean stock was up 1.30% after-hours at $2.31 on Monday.  
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44956197/amazon-price-target-slashed-again-on-wild-card-tariff-concerns?utm_source=articleShare">Amazon Price Target Slashed Again On &#8216;Wild Card&#8217; Tariff Concerns&nbsp;</a></li>
</ul>
Photo: Shutterstock

After-Hours Center

Movers

Transocean Stock Climbs After Mixed Q1 Results: EPS Miss, Revenue Beats

Management

General

ARMN

Aris Mining's Richard Orazietti To Step Down As CFO Following The Completion Of The Company's Q1 2025 Reporting

CVR Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UAN#NYSE">UAN</a>) reported quarterly earnings of $2.56 per share. This is a 115.13 percent increase over earnings of $1.19 per share from the same period last year. The company reported $142.87 million in sales this quarter. This is a 11.91 percent increase over sales of $127.67 million the same period last year.

CVR Partners Q1 EPS $2.56 Up From $1.19 YoY, Sales $142.87M Up From $127.67M YoY

CVR Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVI#NYSE">CVI</a>) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.89) by 34.83 percent. This is a 1550 percent decrease over earnings of $0.04 per share from the same period last year. The company reported quarterly sales of $1.65 billion which beat the analyst consensus estimate of $1.31 billion by 25.82 percent. This is a 11.65 percent decrease over sales of $1.86 billion the same period last year.

CVR Energy Q1 Adj. EPS $(0.58) Beats $(0.89) Estimate, Sales $1.65B Beat $1.31B Estimate

Biotech

NGNE

Neurogene To Give Oral Presentation On Monitoring And Treatment To Reverse Rare Complication of High-Dose Gene Therapy At the ASGCT Annual Meeting

Earnings Misses

Waste Management Q1 Adj. EPS $1.67 Beats $1.62 Estimate, Sales $6.02B Miss $6.12B Estimate

Brown &amp; Brown (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRO#NYSE">BRO</a>) reported quarterly earnings of $1.29 per share which missed the analyst consensus estimate of $1.30 by 0.77 percent. This is a 13.16 percent increase over earnings of $1.14 per share from the same period last year. The company reported quarterly sales of $1.40 billion which met the analyst consensus estimate. This is a 11.61 percent increase over sales of $1.26 billion the same period last year.

Brown & Brown Q1 Adj. EPS $1.29 Misses $1.30 Estimate, Sales $1.40B Inline

Scotiabank analyst Kevin Krishnaratne downgrades Lightspeed Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LSPD#NYSE">LSPD</a>) from Sector Outperform to Sector Perform and lowers the price target from $17 to $11.

Downgrades

Price Target

Analyst Ratings

LSPD

Scotiabank Downgrades Lightspeed Commerce to Sector Perform, Lowers Price Target to $11

<h3>Gainers</h3>
<ul>
<li>Leggett &amp; Platt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEG#NYSE">LEG</a>) shares moved upwards by 17.6% to $8.55 during Monday's after-market session. The market value of their outstanding shares is at $1.1 billion. The company's, Q1 earnings came out today. </li>
<li>Beyond (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYON#NYSE">BYON</a>) shares moved upwards by 16.02% to $4.85. The market value of their outstanding shares is at $257.7 million. As per the news, the Q1 earnings report came out today. </li>
<li>SunCar Tech Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDA#NASDAQ">SDA</a>) shares moved upwards by 15.38% to $3.0. The company's market cap stands at $325.8 million. As per the news, the FY earnings report came out today. </li>
<li>Yoshiharu Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YOSH#NASDAQ">YOSH</a>) stock rose 7.6% to $13.01. The company's market cap stands at $22.4 million. </li>
<li>Gogoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGR#NASDAQ">GGR</a>) stock rose 4.99% to $0.27. The market value of their outstanding shares is at $79.3 million. </li>
<li>Wah Fu Education Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAFU#NASDAQ">WAFU</a>) stock increased by 4.9% to $1.5. The company's market cap stands at $6.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WW International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) stock declined by 12.9% to $0.36 during Monday's after-market session. The company's market cap stands at $28.9 million. </li>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares fell 10.32% to $0.15. The market value of their outstanding shares is at $7.4 million. </li>
<li>Aureus Greenway Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGH#NASDAQ">AGH</a>) stock declined by 6.31% to $0.57. The market value of their outstanding shares is at $7.9 million. </li>
<li>Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) stock fell 5.39% to $0.68. The market value of their outstanding shares is at $4.4 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares declined by 5.27% to $0.0. The market value of their outstanding shares is at $2.8 million. </li>
<li>Grove Collaborative Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GROV#NYSE">GROV</a>) stock fell 5.23% to $1.05. The company's market cap stands at $42.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BYON

GROV

HOFV

Market Index Target Term Securities Linked To The Dow Jones Industrial Average

WAFU

YOSH

12 Consumer Discretionary Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock moved upwards by 40.8% to $1.32 during Monday's after-market session. The market value of their outstanding shares is at $231.0 million. </li>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 8.77% to $0.77. The market value of their outstanding shares is at $61.6 million. </li>
<li>Autonomix Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMIX#NASDAQ">AMIX</a>) stock rose 8.29% to $2.48. The market value of their outstanding shares is at $6.1 million. </li>
<li>Onconetix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONCO#NASDAQ">ONCO</a>) stock rose 7.9% to $0.09. The company's market cap stands at $1.3 million. </li>
<li>Cyclacel Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYCC#NASDAQ">CYCC</a>) shares moved upwards by 6.55% to $0.3. The market value of their outstanding shares is at $4.2 million. </li>
<li>Genfit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNFT#NASDAQ">GNFT</a>) stock increased by 6.16% to $3.79. The market value of their outstanding shares is at $188.9 million. The company's, FY earnings came out 2 days ago. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Anavex Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVXL#NASDAQ">AVXL</a>) shares declined by 12.6% to $8.37 during Monday's after-market session. The company's market cap stands at $712.2 million. </li>
<li>Y-mAbs Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YMAB#NASDAQ">YMAB</a>) shares decreased by 10.38% to $3.8. The market value of their outstanding shares is at $170.1 million. </li>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) shares fell 8.97% to $1.93. The market value of their outstanding shares is at $60.2 million. </li>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares decreased by 8.53% to $0.33. The company's market cap stands at $10.7 million. </li>
<li>DBV Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBVT#NASDAQ">DBVT</a>) shares fell 7.31% to $8.5. The market value of their outstanding shares is at $232.3 million. </li>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock declined by 6.95% to $2.41. The company's market cap stands at $6.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMIX

AVXL

CTMX

CYCC

DBVT

FORA

GNFT

LIPO

ONCO

RLMD

TVGN

YMAB

12 Health Care Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares increased by 10.0% to $1.1 during Monday's after-market session. The market value of their outstanding shares is at $19.0 million. </li>
<li>Royalty Management Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMCO#NASDAQ">RMCO</a>) stock increased by 7.7% to $1.26. The company's market cap stands at $18.8 million. </li>
<li>Odyssey Marine Explr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMEX#NASDAQ">OMEX</a>) shares moved upwards by 7.16% to $1.42. The company's market cap stands at $41.3 million. </li>
<li>Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) shares increased by 4.92% to $0.52. The company's market cap stands at $27.4 million. </li>
<li>Icon Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICON#NASDAQ">ICON</a>) shares moved upwards by 4.87% to $2.15. The market value of their outstanding shares is at $4.6 million. As per the news, the FY earnings report came out 3 days ago. </li>
<li>BioNexus Gene Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGLC#NASDAQ">BGLC</a>) shares moved upwards by 4.79% to $2.84. The market value of their outstanding shares is at $5.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>WF Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WFF#NASDAQ">WFF</a>) shares decreased by 7.9% to $3.52 during Monday's after-market session. The company's market cap stands at $87.8 million. </li>
<li>Zeo Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZEO#NASDAQ">ZEO</a>) stock declined by 7.37% to $1.51. The market value of their outstanding shares is at $21.1 million. </li>
<li>OceanPal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OP#NASDAQ">OP</a>) shares decreased by 5.84% to $0.71. The company's market cap stands at $5.3 million. </li>
<li>Azul (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZUL#NYSE">AZUL</a>) stock declined by 5.68% to $0.83. The market value of their outstanding shares is at $255.7 million. </li>
<li>VCI Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VCIG#NASDAQ">VCIG</a>) stock fell 4.98% to $4.5. The market value of their outstanding shares is at $12.6 million. </li>
<li>Kforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KFRC#NYSE">KFRC</a>) stock fell 4.85% to $40.69. The company's market cap stands at $777.6 million. As per the news, the Q1 earnings report came out today. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AZUL

BGLC

ICON

KFRC

OMEX

RMCO

SDST

VCIG

ZBAI

12 Industrials Stocks Moving In Monday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Sagtec Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGT#NASDAQ">SAGT</a>) shares moved upwards by 7.3% to $4.12 during Monday's after-market session. The company's market cap stands at $51.7 million. </li>
<li>Sigmatron Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMA#NASDAQ">SGMA</a>) shares rose 5.88% to $1.26. The market value of their outstanding shares is at $7.7 million. </li>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) stock increased by 5.13% to $4.71. The market value of their outstanding shares is at $8.2 million. </li>
<li>Mobix Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOBX#NASDAQ">MOBX</a>) shares increased by 4.99% to $0.76. The market value of their outstanding shares is at $31.0 million. </li>
<li>Taoping (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TAOP#NASDAQ">TAOP</a>) shares rose 4.95% to $0.24. The market value of their outstanding shares is at $3.1 million. </li>
<li>Veritone (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERI#NASDAQ">VERI</a>) stock increased by 4.83% to $2.17. The market value of their outstanding shares is at $97.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock decreased by 12.7% to $1.9 during Monday's after-market session. The market value of their outstanding shares is at $49.0 million. </li>
<li>Sanmina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANM#NASDAQ">SANM</a>) shares decreased by 8.34% to $74.0. The company's market cap stands at $3.9 billion. As per the press release, Q2 earnings came out today. </li>
<li>Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) stock declined by 6.62% to $1.27. The market value of their outstanding shares is at $25.2 million. </li>
<li>Ultra Clean Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) stock fell 6.06% to $20.95. The market value of their outstanding shares is at $945.5 million. The company's, Q1 earnings came out today. </li>
<li>Mawson Infra Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIGI#NASDAQ">MIGI</a>) shares decreased by 5.43% to $0.68. The company's market cap stands at $12.7 million. </li>
<li>908 Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASS#NASDAQ">MASS</a>) stock declined by 4.97% to $5.07. The company's market cap stands at $179.1 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INTZ

MASS

MAWSON INFRSTRUCTURE GRP by Mawson Infrastructure Group Inc.

MIGI

MOBX

SAGT

SANM

SGMA

TAOP

UCTT

VERI

12 Information Technology Stocks Moving In Monday's After-Market Session

Nucor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) reported first-quarter financial results after the market close on Monday. Here&#8217;s what you need to know <a href="https://www.benzinga.com/pressreleases/25/04/n45053335/nucor-reports-results-for-the-first-quarter-of-2025">from the report</a>.
<ul>
<li>Q1 Revenue: $7.83 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $7.23 billion</li>
</ul>
<ul>
<li>Q1 Adjusted EPS: 77 cents, versus estimates of 64 cents</li>
</ul>
Total revenue was down 4% on a year-over-year basis. The steel manufacturer said it shipped approximately 6.83 million tons to outside customers during the quarter. Average sales price per ton decreased&nbsp;12%&nbsp;year-over-year, while total steel mill shipments increased 10% year-over-year.
Nucor repurchased approximately 2.3 million shares at an average price of $133.17 per share in the quarter. The steel company had $806 million remaining on its buyback as of April 5. Nucor ended the quarter with $4.06 billion in cash, cash equivalents and short-term investments on hand.&nbsp;
&#8220;Despite recent financial market volatility, Nucor is seeing solid demand for the steel and steel products we manufacture. Our healthy balance sheet and diverse product portfolio position us well, even in uncertain times,&#8221; said&nbsp;Leon Topalian, chair, president and CEO of Nucor.
See Also: <a href="https://www.benzinga.com/news/management/25/04/45053723/nxp-semiconductors-reports-q1-earnings-very-uncertain-operating-environment-tied-to-tariffs-ceo-transition-shares-fall">NXP Semiconductors Reports Q1 Earnings: &#8216;Very Uncertain&#8217; Operating Environment Tied To Tariffs, CEO Transition, Shares Fall</a>
Outlook: Nucor expects second-quarter earnings to increase across all three operating segments (steel mills, steel products and raw materials) compared to the first quarter. 
The stock reaction is somewhat muted, likely due to the company already reporting preliminary results for the quarter in March. Executives will further discuss the quarter on a call with investors and analysts Tuesday morning at 10 a.m. ET.
NUE Price Action: <a href="http://benzinga.com/quote/nue" target="_blank" rel="noreferrer noopener">Nucor shares</a> were up 1.02% after-hours, trading at $117.76 at the time of publication Monday, per <a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Photo: saweang.w/Shutterstock.

Commodities

Nucor Q1 Earnings: Revenue Beat, EPS Beat, 'Solid' Steel Demand And More

Travelzoo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TZOO#NASDAQ">TZOO</a>) is preparing to release its quarterly earnings on Tuesday, 2025-04-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Travelzoo to report an earnings per share (EPS) of $0.25.
Investors in Travelzoo are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.04, leading to a 10.38% increase in the share price the following trading session.
Here's a look at Travelzoo's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.30</td>
<td>0.20</td>
<td>0.22</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.26</td>
<td>0.26</td>
<td>0.23</td>
<td>0.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>3.0%</td>
<td>7.000000000000001%</td>
<td>-1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874187_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Travelzoo were trading at $13.32 as of April 25. Over the last 52-week period, shares are up 40.52%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/TZOO/earnings">To track all earnings releases for Travelzoo visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TZOO

A Peek at Travelzoo's Future Earnings

Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Intrusion will report an earnings per share (EPS) of $-0.11. 
Anticipation surrounds Intrusion's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Historical Earnings Performance</h3>
The company's EPS missed by $0.15 in the last quarter, leading to a 21.3% drop in the share price on the following day.
Here's a look at Intrusion's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.21</td>
<td>-0.42</td>
<td>-0.55</td>
<td>-1.20</td>
<td>-2.2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.36</td>
<td>-0.35</td>
<td>-0.53</td>
<td>-0.94</td>
<td>-1.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-21.0%</td>
<td>-15.0%</td>
<td>19.0%</td>
<td>-26.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874178_0.png" alt="eps graph" />
<h3>Performance of Intrusion Shares</h3>
Shares of Intrusion were trading at $1.26 as of April 25. Over the last 52-week period, shares are down 21.84%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/INTZ/earnings">To track all earnings releases for Intrusion visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Peek at Intrusion's Future Earnings

Rocky Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKY#NASDAQ">RCKY</a>) is set to give its latest quarterly earnings report on Tuesday, 2025-04-29. Here's what investors need to know before the announcement.
Analysts estimate that Rocky Brands will report an earnings per share (EPS) of $0.52. 
Investors in Rocky Brands are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.03 in the last quarter, leading to a 10.9% drop in the share price on the following day.
Here's a look at Rocky Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.22</td>
<td>0.98</td>
<td>0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.19</td>
<td>0.77</td>
<td>0.17</td>
<td>0.41</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-11.0%</td>
<td>-27.0%</td>
<td>-2.0%</td>
<td>28.000000000000004%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745874157_0.png" alt="eps graph" />
<h3>Tracking Rocky Brands's Stock Performance</h3>
Shares of Rocky Brands were trading at $13.7 as of April 25. Over the last 52-week period, shares are down 47.77%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/RCKY/earnings">To track all earnings releases for Rocky Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RCKY

Rocky Brands Earnings Preview

Press Releases

Genelux Corporation to Participate in the 2024 Maxim Healthcare Virtual Summit

Genelux Corporation Announces First Patient Dosed in Phase 2 Trial Evaluating Systemic Therapy with Olvi-Vec in Non-Small Cell Lung Cancer

Genelux Corporation Reports Third Quarter 2024 Financial Results and Provides General Business Updates

Frazier Life Sciences Appoints John Smither and Jim Williams as Senior Advisors

Genelux Corporation to Participate in a Fireside Chat with H.C. Wainwright

Genelux Corporation Announces New Chief Financial Officer

Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease

Genelux and Newsoara Announce Positive Preliminary Phase 1b/2 Data of Olvi-Vec in Advanced Small-Cell Lung Cancer

Genelux Corporation Announces Pricing of $10.5 Million Underwritten Offering of Common Stock

Genelux Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Comments

Genelux

Genelux (GNLX) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL